RD
Robert Doebele
Medical Oncology
Credentials: · · · ·
History
2004–2006- 2001–2004
Internal Medicine
Research
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
New England Journal of Medicine · 2018 · 2,193 citations
Crizotinib in ROS1-rearranged non-small-cell lung cancer
New England Journal of Medicine · 2014 · 1,560 citations
The Lancet Oncology · 2020 · First of 39 authors · 1,363 citations
56 papers
36 papers
20 papers
- AD
14 papers
- CM
13 papers · 2 as a fellow
13 papers · 11 as a resident
11 papers
- AW
11 papers · 11 as a resident
Grants
- 2016–2022
The Role of EGFR as a Mechanism of Therapeutic Resistance in Gene Fusion Positive Lung Cancer.
National Cancer Institute · R01
Contact PI · $2M · University of Colorado Denver
- 1997–2020